Barclays initiated coverage of Gilead (GILD) with an Equal Weight rating and $155 price target The company is back to doing what it does best, which is developing treatments for infectious diseases, the analyst tells investors in a research note. However, Barclays views Gilead’s valuation as “rich” at current share levels.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead price target raised to $170 from $140 at Mizuho
- Gilead Sciences: Strong HIV Growth Priced In, Diversification Still Limited Justifying Hold Rating
- Gilead price target raised to $175 from $155 at UBS
- XBI vs. IBB: Which Biotech ETF do Analysts Prefer in 2026?
- Gilead Sciences Earnings Call: HIV Strength, New Catalysts